Pharmacological Research,
Journal Year:
2024,
Volume and Issue:
unknown, P. 107561 - 107561
Published: Dec. 1, 2024
Gut
microbial
dysbiosis
or
altered
gut
consortium,
in
schizophrenia
suggests
a
pathogenic
role
through
the
gut-brain
axis,
influencing
neuroinflammatory
and
neurotransmitter
pathways
critical
to
psychotic,
affective,
cognitive
symptoms.
Paradoxically,
conventional
psychotropic
interventions
may
exacerbate
this
dysbiosis,
with
antipsychotics,
particularly
olanzapine,
demonstrating
profound
effects
on
architecture
disruption
of
bacterial
phyla
ratios,
diminished
taxonomic
diversity,
attenuated
short-chain
fatty
acid
synthesis.
To
address
these
challenges,
novel
therapeutic
strategies
targeting
microbiome,
encompassing
probiotic
supplementation,
prebiotic
compounds,
faecal
microbiota
transplantation,
rationalised
co-pharmacotherapy,
show
promise
attenuating
antipsychotic-induced
metabolic
disruptions
while
enhancing
efficacy.
Harnessing
such
insights,
precision
medicine
approaches
transform
antipsychotic
prescribing
practices
by
identifying
patients
at
risk
side
based
their
profiles.
This
IUPHAR
review
collates
current
literature
landscape
axis
its
intricate
relationship
advocating
for
integrating
microbiome
assessments
management.
Such
fundamental
shift
proposing
microbiome-informed
prescriptions
optimise
efficacy
reduce
adverse
impacts
would
align
treatments
safety,
prioritising
'gut-neutral'
gut-favourable
drugs
safeguard
long-term
patient
outcomes
therapy.
Genes,
Journal Year:
2025,
Volume and Issue:
16(4), P. 439 - 439
Published: April 7, 2025
Background:
Psychosis,
particularly
schizophrenia
(SZ),
is
influenced
by
genetic
and
environmental
factors.
The
neurodevelopmental
hypothesis
suggests
that
factors
affect
neuronal
circuit
connectivity
during
perinatal
periods,
hence
causing
the
onset
of
diseases.
In
this
study,
we
performed
a
genome-wide
association
study
(GWAS)
in
sample
first
episode
psychosis
(FEP).
Methods:
A
147
individuals
diagnosed
with
non-affective
102
controls
were
recruited
assessed.
After
venous
blood
DNA
extraction,
samples
genotyped.
Genetic
data
underwent
quality
controls,
genotype
imputation,
case-control
(GWAS).
GWAS,
results
investigated
using
an
silico
functional
mapping
annotation
approach.
Results:
Our
GWAS
showed
27
variants
across
13
chromosomes
at
significance
(p
<
1
×
10−7)
total
1976
candidate
188
genes
suggestive
10−5),
mostly
non-coding
or
intergenic
regions.
Gene-based
tests
reported
SUFU
=
4.8
NCAN
1.6
10−5)
genes.
Gene-sets
enrichment
analyses
associations
early
stages
life,
spanning
from
12
to
24
post-conception
weeks
1.4
10−3)
late
prenatal
period
10−3),
favor
hypothesis.
Moreover,
several
matches
Catalog
strictly
related
traits,
such
as
SZ,
well
autism
spectrum
disorder,
which
shares
some
overlap,
risk
factors,
neuroticism
alcohol
dependence.
Conclusions:
resulting
consequent
analysis
displayed
common
liability
between
psychosis,
sum,
our
investigation
provided
novel
hints
supporting
SZ
and—in
general—in
psychoses.
Frontiers in Psychiatry,
Journal Year:
2024,
Volume and Issue:
15
Published: April 23, 2024
Schizophrenia
is
a
serious
mental
health
disorder
that
confers
one
of
the
highest
mortality
rates
all
psychiatric
illnesses.
Although
disorder’s
psychotic
symptoms
are
treatable
with
conventional
antipsychotics,
they
remain
incurable.
Moreover,
medication
adherence
poor,
and
individuals
schizophrenia
choose
to
self-medicate
illicit
substances,
including
cannabis.
It
well-established
delta-9-tetrahydrocannabinol
(delta-9-THC)
component
cannabis
elicits
psychotomimetic
effects
at
high
doses;
worsens
schizophrenia-related
psychosis;
commonly
develops
into
use
in
schizophrenia;
increases
risk
earlier-onset
those
harboring
genetic
susceptibility.
However,
derivatives
such
as
cannabidiol
(CBD).
These
products
seem
alleviate
relieve
adverse
side
antipsychotic
medications.
Therefore,
notion
has
gained
traction
potential
utility
cannabis-derived
(CBD)
adjunct
treatment
reduce
schizophrenia-associated
psychosis
other
symptoms.
Currently,
preclinical
clinical
data
inconclusive.
The
present
review
distinguishes
mechanisms
underlying
vs.
cannabis-induced
reviews
evidence
for
delta-9-THC-mediated
exacerbation
CBD-mediated
amelioration
describes
approaches
incorporating
CBD
therapeutic
regimen
safe
efficacious
manner.
Pharmacological Research,
Journal Year:
2024,
Volume and Issue:
unknown, P. 107561 - 107561
Published: Dec. 1, 2024
Gut
microbial
dysbiosis
or
altered
gut
consortium,
in
schizophrenia
suggests
a
pathogenic
role
through
the
gut-brain
axis,
influencing
neuroinflammatory
and
neurotransmitter
pathways
critical
to
psychotic,
affective,
cognitive
symptoms.
Paradoxically,
conventional
psychotropic
interventions
may
exacerbate
this
dysbiosis,
with
antipsychotics,
particularly
olanzapine,
demonstrating
profound
effects
on
architecture
disruption
of
bacterial
phyla
ratios,
diminished
taxonomic
diversity,
attenuated
short-chain
fatty
acid
synthesis.
To
address
these
challenges,
novel
therapeutic
strategies
targeting
microbiome,
encompassing
probiotic
supplementation,
prebiotic
compounds,
faecal
microbiota
transplantation,
rationalised
co-pharmacotherapy,
show
promise
attenuating
antipsychotic-induced
metabolic
disruptions
while
enhancing
efficacy.
Harnessing
such
insights,
precision
medicine
approaches
transform
antipsychotic
prescribing
practices
by
identifying
patients
at
risk
side
based
their
profiles.
This
IUPHAR
review
collates
current
literature
landscape
axis
its
intricate
relationship
advocating
for
integrating
microbiome
assessments
management.
Such
fundamental
shift
proposing
microbiome-informed
prescriptions
optimise
efficacy
reduce
adverse
impacts
would
align
treatments
safety,
prioritising
'gut-neutral'
gut-favourable
drugs
safeguard
long-term
patient
outcomes
therapy.
